Shire gets EMA Committee positive opinion for Intuniv to treat ADHD
The CHMP’s positive opinion is based on results from three Phase 3 pivotal studies investigating the short- and long-term safety and efficacy of Intuniv in children and adolescents
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).
The patent covers a method of treating eye conditions using EyeGate’s proprietary Dexamethasone Phosphate pharmaceutical formulation delivered by ocular iontophoresis. The patent is not limited to any particular
Technivie is an all-oral, interferon-free, direct-acting antiviral treatment consisting of the fixed-dose combination of paritaprevir/ritonavir (150/100mg) co-formulated with ombitasvir (25mg) dosed once daily and taken with a meal,